Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Mansun
M
Law
Toshiaki
T
Maruyama
Jamie
J
Lewis
Erick
E
Giang
Alexander W
AW
Tarr
Zania
Z
Stamataki
Pablo
P
Gastaminza
Francis V
FV
Chisari
Ian M
IM
Jones
Robert I
RI
Fox
Jonathan K
JK
Ball
Jane A
JA
McKeating
Norman M
NM
Kneteman
Dennis R
DR
Burton
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000939:Epitopes / Q000737:chemistry; D016174:Hepacivirus / Q000378:metabolism*; D006508:Hepatitis Antibodies / Q000737:chemistry*; D006526:Hepatitis C / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D051379:Mice; D009500:Neutralization Tests; D051381:Rats; D013045:Species Specificity; D014761:Viral Hepatitis Vaccines
D000911:Antibodies, Monoclonal; D000939:Epitopes; D006508:Hepatitis Antibodies; D007074:Immunoglobulin G; D014761:Viral Hepatitis Vaccines